Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Clotet

Showing results (181-190 of 263) with videos related to

Pageof 27
Sort By:
HIV Medicine|January 18, 2008
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999A Mocroft, A Horban, B Clotet, et al.
AIDS (London, England)|December 12, 2001
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patientsA N Phillips, C Pradier, A Lazzarin, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individualsP Echeverría, E Gómez-Mora, S Roura, et al.
AIDS (London, England)|June 21, 2001
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infectionL Ruiz, G Carcelain, J Martínez-Picado, et al.
HIV Medicine|May 20, 2008
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot studyJ M Llibre, A Bonjoch, J Iribarren, et al.
Antiviral Therapy|February 22, 2000
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral loadA Rubio, M Gómez-Cano, T Puig, et al.
Clinical and Experimental Immunology|August 16, 2006
Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10G Coma, R Peña, J Blanco, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|September 10, 1998
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patientsC Vidal, F García, J M Gatell, et al.
HIV Medicine|August 19, 2011
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*A Cozzi-Lepri, Paredes, A N Phillips, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|April 30, 2010
Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected womenM P Cañadas, S Videla, L Darwich, et al.
Pageof 27

Showing results (181-190 of 263) with videos related to

Sort By:
Pageof 27
HIV Medicine|January 18, 2008
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999A Mocroft, A Horban, B Clotet, et al.
AIDS (London, England)|December 12, 2001
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patientsA N Phillips, C Pradier, A Lazzarin, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individualsP Echeverría, E Gómez-Mora, S Roura, et al.
AIDS (London, England)|June 21, 2001
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infectionL Ruiz, G Carcelain, J Martínez-Picado, et al.
HIV Medicine|May 20, 2008
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot studyJ M Llibre, A Bonjoch, J Iribarren, et al.
Antiviral Therapy|February 22, 2000
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral loadA Rubio, M Gómez-Cano, T Puig, et al.
Clinical and Experimental Immunology|August 16, 2006
Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10G Coma, R Peña, J Blanco, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|September 10, 1998
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patientsC Vidal, F García, J M Gatell, et al.
HIV Medicine|August 19, 2011
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*A Cozzi-Lepri, Paredes, A N Phillips, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|April 30, 2010
Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected womenM P Cañadas, S Videla, L Darwich, et al.
Pageof 27